Literature DB >> 19545286

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).

Jean-Christophe Ianotto, Jean-Jacques Kiladjian, Jean-Louis Demory, Lydia Roy, Françoise Boyer, Jerôme Rey, Brigitte Dupriez, Christian Berthou, Jean-François Abgrall.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545286     DOI: 10.1111/j.1365-2141.2009.07745.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  14 in total

1.  Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients.

Authors:  Krisstina Gowin; Prakash Thapaliya; Jan Samuelson; Claire Harrison; Deepti Radia; Bjorn Andreasson; John Mascarenhas; Alessandro Rambaldi; Tiziano Barbui; Catherine J Rea; John Camoriano; Amy Gentry; Jean-Jacques Kiladjian; Casey O'Connell; Ruben Mesa
Journal:  Haematologica       Date:  2012-03-14       Impact factor: 9.941

Review 2.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors.

Authors:  Swarna Mehrotra; Bhumika Sharma; Sonali Joshi; Barbara Kroczynska; Beata Majchrzak; Brady L Stein; Brandon McMahon; Jessica K Altman; Jonathan D Licht; Darren P Baker; Elizabeth A Eklund; Amittha Wickrema; Amit Verma; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2013-06-28       Impact factor: 5.157

4.  Myelofibrosis 2012: it's complicated.

Authors:  Harper G Hubbeling; Dale M Frank; Elizabeth O Hexner
Journal:  Ther Adv Hematol       Date:  2012-06

5.  Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis.

Authors:  Jan Philipp Bewersdorf; Smith Giri; Rong Wang; Nikolai Podoltsev; Robert T Williams; Raajit K Rampal; Martin S Tallman; Amer M Zeidan; Maximilian Stahl
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2020-05-28

6.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

7.  The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

Authors:  Min Lu; Lijuan Xia; Yan Li; Xiaoli Wang; Ronald Hoffman
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

8.  Emerging therapeutic options for myelofibrosis: a Canadian perspective.

Authors:  Vikas Gupta; Lynda Foltz; Shireen Sirhan; Lambert Busque; A Robert Turner
Journal:  Am J Blood Res       Date:  2012-09-23

Review 9.  Emerging drugs for myelofibrosis.

Authors:  Ehab Atallah; Srdan Verstovsek
Journal:  Expert Opin Emerg Drugs       Date:  2012-12       Impact factor: 4.191

Review 10.  The evolving treatment paradigm in myelofibrosis.

Authors:  Ruben A Mesa
Journal:  Leuk Lymphoma       Date:  2012-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.